Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Influenza, Human
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| FLU Q-QIV-013 | N/A |
Active, not recruiting |
Influenza, Human |
None |
2025-07-06 |
Start Date|Treatments|Trial Status |
|
| FLU Q-QIV-006 PRI | N/A |
Active, not recruiting |
Influenza, Human |
None |
2025-07-05 |
Start Date|Treatments|Trial Status |
|
| NCT01974895 | P2 |
Completed |
Influenza, Human |
2014-02-27 |
2019-03-20 |
Treatments |
|
| NCT02242643 | P3 |
Completed |
Influenza, Human |
2015-03-16 |
2019-03-20 |
Treatments |
|
| NCT01711736 | P3 |
Completed |
Influenza, Human |
2013-02-21 |
2021-11-02 |
Primary Endpoints|Treatments |
|
| NCT01218308 | P3 |
Completed |
Influenza, Human |
2012-01-09 |
2019-03-19 |
Treatments |
|
| NCT01198756 | P3 |
Completed |
Influenza, Human |
2011-07-01 |
2019-03-19 |
Treatments |
|
| NCT01196975 | P3 |
Completed |
Influenza, Human |
2011-01-25 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|